4//SEC Filing
Sullivan Ryan T 4
Accession 0001104659-19-065554
CIK 0001270073other
Filed
Nov 18, 7:00 PM ET
Accepted
Nov 19, 7:00 PM ET
Size
10.5 KB
Accession
0001104659-19-065554
Insider Transaction Report
Form 4
Sullivan Ryan T
General Counsel
Transactions
- Exercise/Conversion
Option to Purchase Common Stock
2019-11-19−8,325→ 26,475 totalExercise: $53.41Exp: 2028-02-13→ Common Stock (8,325 underlying) - Exercise/Conversion
Common Stock
2019-11-19$53.41/sh+8,325$444,638→ 34,043 total - Sale
Common Stock
2019-11-19$85.00/sh−8,325$707,625→ 25,718 total - Sale
Common Stock
2019-11-19$85.00/sh−3,829$325,465→ 21,889 total
Footnotes (2)
- [F1]This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Start Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Start Date was February 13, 2018.
Documents
Issuer
INTERCEPT PHARMACEUTICALS, INC.
CIK 0001270073
Entity typeother
Related Parties
1- filerCIK 0001578823
Filing Metadata
- Form type
- 4
- Filed
- Nov 18, 7:00 PM ET
- Accepted
- Nov 19, 7:00 PM ET
- Size
- 10.5 KB